Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.

Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, Poupon R, Housset C, Corpechot C, Chazouillères O.

Clin Res Hepatol Gastroenterol. 2018 Dec;42(6):521-528. doi: 10.1016/j.clinre.2018.06.009. Epub 2018 Aug 9.

PMID:
30100231
2.

New therapies target the toxic consequences of cholestatic liver disease.

Jansen PLM.

Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):277-285. doi: 10.1080/17474124.2018.1424538. Epub 2018 Jan 10. Review.

PMID:
29310470
3.

[Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].

Hohenester S, Beuers U.

Internist (Berl). 2017 Aug;58(8):805-825. doi: 10.1007/s00108-017-0287-z. Review. German.

PMID:
28721532
4.

Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate.

Dai M, Yang J, Xie M, Lin J, Luo M, Hua H, Xu G, Lin H, Song D, Cheng Y, Guo B, Zhao J, Gonzalez FJ, Liu A.

Br J Pharmacol. 2017 Sep;174(18):3000-3017. doi: 10.1111/bph.13928. Epub 2017 Aug 10.

5.

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.

Bolier R, de Vries ES, Parés A, Helder J, Kemper EM, Zwinderman K, Elferink RPO, Beuers U; Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group.

Trials. 2017 May 23;18(1):230. doi: 10.1186/s13063-017-1966-8.

6.

Factors predictive of the efficacy of bezafibrate therapy in patients with primary sclerosing cholangitis.

Mizuno S, Isayama H, Hirano K, Watanabe T, Takahara N, Kogure H, Matsubara S, Nakai Y, Tada M, Koike K.

Hepatol Res. 2017 Oct;47(11):1102-1107. doi: 10.1111/hepr.12846. Epub 2017 Jan 17.

PMID:
27874998
7.

Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis.

Mizuno S, Hirano K, Isayama H, Watanabe T, Yamamoto N, Nakai Y, Sasahira N, Tada M, Omata M, Koike K.

J Hepatobiliary Pancreat Sci. 2015 Oct;22(10):766-70. doi: 10.1002/jhbp.281. Epub 2015 Aug 21.

PMID:
26173026
8.

[A case of secondary sclerosing cholangitis caused by chemotherapy with nab-paclitaxel].

Matsuo T, Nakamura Y, Suzuki K.

Nihon Shokakibyo Gakkai Zasshi. 2015 May;112(5):888-95. doi: 10.11405/nisshoshi.112.888. Review. Japanese.

PMID:
25947025
9.

Overlap of IgG4-related sclerosing cholangitis and primary biliary cirrhosis.

Takemoto R, Miyake Y, Harada K, Nakanuma Y, Moriya A, Ando M, Hirohata M, Yamamoto K.

Intern Med. 2014;53(13):1429-33. Epub 2014 Jun 15.

10.

[Ischemic cholangitis in intensive care unit: favourable outcome with ursodesoxycholic acid and fenofibrate].

Bélénotti P, Guervilly C, Grandval P, Benyamine A, Ene N, Serratrice J, Petit P, Laugier R, Papazian L, Weiller PJ.

Rev Med Interne. 2013 Feb;34(2):110-3. doi: 10.1016/j.revmed.2012.10.376. Epub 2012 Nov 30. French.

PMID:
23200798
11.

Bezafibrate for the treatment of primary sclerosing cholangitis.

Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K.

J Gastroenterol. 2010 Jul;45(7):758-62. doi: 10.1007/s00535-010-0204-x. Epub 2010 Feb 3.

PMID:
20127368
12.

Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.

Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N.

J Gastroenterol. 2006 Jul;41(7):686-92.

PMID:
16933007
13.

[Bezafibrate alone is an effective first-line therapy for primary sclerosing cholangitis: a case report].

Gondoh K, Ono T, Miyakoda K, Mukasa M, So A, Imamura K, Sata M.

Nihon Shokakibyo Gakkai Zasshi. 2006 Jun;103(6):643-9. Japanese.

PMID:
16800287
14.

Efficacy of bezafibrate in a patient with primary sclerosing cholangitis.

Kurihara T, Maeda A, Shigemoto M, Yamashita K, Kamatani N.

J Gastroenterol. 2003;38(3):300-1. No abstract available.

PMID:
12693383
15.

Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports).

Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S, Osaki Y, Tomono N, Hachiya T, Shimizu T.

Am J Gastroenterol. 2002 Jul;97(7):1849-51. No abstract available.

PMID:
12135056
16.

[A case of primary sclerosing cholangitis presenting transient hypoperfusion and treated with bezafibrate beneficially].

Kita R, Osaki Y, Hachiya T, Kimura T, Komekado H, Sawabu T, Hatano H, Tsuji K, Maruo T, Kokuryu H, Takamatsu S, Fukuyama T, Tomono N, Komibuchi T, Shimizu T.

Nihon Shokakibyo Gakkai Zasshi. 2002 Feb;99(2):170-8. Japanese. No abstract available.

PMID:
11877955

Supplemental Content

Loading ...
Support Center